Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case–control study with hydroxychloroquine blood-level analysis
- 23 May 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 59 (12), 3807-3816
- https://doi.org/10.1093/rheumatology/keaa157
Abstract
Objective HCQ is an essential medication in SLE, proven to lengthen survival and reduce flares. Its use, however, is limited by its rare but severe ophthalmological complications. Here, we aimed to analyse factors associated with HCQ retinopathy including HCQ blood levels. Methods This case–control study compared SLE patients with and without HCQ retinopathy, defined by abnormal results for at least two of the following ophthalmological tests: automated visual fields, spectral-domain optical coherence tomography (SD-OCT), multifocal electroretinogram (mfERG) and fundus autofluorescence. We compared clinical and laboratory findings to assess risk factors for HCQ retinopathy. Results The study included 23 patients with confirmed retinopathy (cases) and 547 controls. In the univariate analysis, age (P < 0.001), height (P = 0.045), creatinine clearance (P < 0.001), haemoglobin concentration (P = 0.01), duration of HCQ intake, (P < 0.001), higher cumulative HCQ dose (P < 0.001) and geographical origin (West Indies and sub-Saharan Africa) (P = 0.007) were associated with the risk of retinopathy, while HCQ blood levels were not. In the multivariate analysis, only cumulative dose (P = 0.016), duration of intake (P = 0.039), creatinine clearance (P = 0.002) and geographical origin (P < 0.0001, odds ratio 8.7) remained significantly associated with retinopathy. Conclusion SLE patients on HCQ should be closely monitored for retinopathy, especially those from the West Indies or sub-Saharan Africa, or with renal insufficiency, longer HCQ intake or a high cumulative dose. Although reducing the daily dose of HCQ in patients with persistently high HCQ blood levels seems logical, these concentrations were not associated with retinopathy in this study with controls adherent to treatment.Keywords
Funding Information
- Clinical Research Unit of Pitié-Salpêtrière Hospital
This publication has 38 references indexed in Scilit:
- Revised Recommendations on Screening for Chloroquine and Hydroxychloroquine RetinopathyOphthalmology, 2011
- Evaluation of risk factors for retinal damage due to chloroquine and hydroxychloroquineBritish Journal of Ophthalmology, 2010
- Clinical characteristics of hydroxychloroquine retinopathyBritish Journal of Ophthalmology, 2010
- Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic reviewAnnals Of The Rheumatic Diseases, 2008
- Using multifocal ERG ring ratios to detect and follow Plaquenil retinal toxicity: a reviewDocumenta Ophthalmologica, 2008
- Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosusAnnals Of The Rheumatic Diseases, 2007
- Hydroxychloroquine concentration–response relationships in patients with rheumatoid arthritisArthritis & Rheumatism, 2002
- Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1997
- Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practiceArthritis & Rheumatism, 1997
- Hydroxychloroquine and visual screening in a rheumatology outpatient clinicAnnals Of The Rheumatic Diseases, 1997